Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling

International Journal of Oncology

Volumn 45, Issue 1, 2014, Pages 177-188

  Hsu, Fei Ting ^a   Liu, Y U Chang ^a   Chiang, I Tsang ^a,b   Liu, Ren Shyan ^c   Wang, Hsin Ell ^a   Lin, Wuu Jyh ^d   Hwang, Jeng Jong ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

Author keywords

Hepatocellular carcinoma; NF B; SAHA; Sorafenib; Vorinostat

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE; RED FLUORESCENT PROTEIN; SORAFENIB; THYMIDINE KINASE; VORINOSTAT; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; HYDROXAMIC ACID; NF-KAPPA B KINASE; NICOTINAMIDE; PROTEIN SERINE THREONINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOMA CELL LINE; CELL VIABILITY; CELL VIABILITY ASSAY; CONTROLLED STUDY; DNA FRAGMENTATION; DNA FRAGMENTATION ASSAY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MEGADOSE; EX VIVO STUDY; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING; WHOLE BODY AUTORADIOGRAPHY; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; EXPERIMENTAL LIVER NEOPLASM; LIVER TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; HYDROXAMIC ACIDS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN-SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902577006     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2423     Document Type: Article

References (33)

1. Feng M and Ben-Josef E: Radiation therapy for hepatocellular carcinoma. Semin Radiat Oncol 21: 271-277, 2011.
2. Zhang X, Yang XR, Huang XW, et al: Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int 11: 458-466, 2012.
3. Kanno K, Kanno S, Nitta H, et al: Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells. Oncol Rep 28: 867-873, 2012.
4. Wu J, Du C, Lv Z, et al: The up-regulation of histone deacetylase 8 promotes proliferation and inhibits apoptosis in hepatocellular carcinoma. Dig Dis Sci 58: 3545-3553, 2013.
5. Rikimaru T, Taketomi A, Yamashita Y, et al: Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology 72: 69-74, 2007.
6. Wu LM, Yang Z, Zhou L, et al: Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One 5: e14460, 2010.
7. Machado MC, Bellodi-Privato M, Kubrusly MS, et al: Valproic acid inhibits human hepatocellular cancer cells growth in vitro and in vivo. J Exp Ther Oncol 9: 85-92, 2011.
8. Coradini D and Speranza A: Histone deacetylase inhibitors for treatment of hepatocellular carcinoma. Acta Pharmacol Sin 26: 1025-1033, 2005.
9. Yoshida K, Sasaki R, Nishimura H, et al: Nuclear factor-kappaB expression as a novel marker of radioresistance in early-stage laryngeal cancer. Head Neck 32: 646-655, 2010.
10. Ni W, Chen B, Zhou G, et al: Overexpressed nuclear BAG-1 in human hepatocellular carcinoma is associated with poor prognosis and resistance to doxorubicin. J Cell Biochem 114: 2120-2130, 2013.
11. Zhang G, Park MA, Mitchell C, et al: Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res 14: 5385-5399, 2008.
12. Spratlin JL, Pitts TM, Kulikowski GN, et al: Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. Anticancer Res 31: 1093-1103, 2011.
13. Wang WH, Chiang IT, Liu YC, et al: Simultaneous imaging of temporal changes of NF-kappaB activity and viable tumor cells in Huh7/NF-kappaB-tk-luc2/ rfp tumor-bearing mice. In vivo 27: 339-350, 2013.
14. Dai Y, Rahmani M, Dent P and Grant S: Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 25: 5429-5444, 2005.
15. Domingo-Domenech J, Pippa R, Tapia M, Gascon P, Bachs O and Bosch M: Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. Breast Cancer Res Treat 112: 53-62, 2008.
16. Dai Y, Guzman ML, Chen S, et al: The NF (nuclear factor)- kappaB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. Br J Haematol 151: 70-83, 2010.
17. Dai Y, Chen S, Wang L, et al: Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors. J Biol Chem 286: 34036-34050, 2011.
18. Schelman WR, Traynor AM, Holen KD, et al: A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Invest New Drugs 31: 1539-1546, 2013.
19. Deming DA, Ninan J, Bailey HH, et al: A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Invest New Drugs 32: 323-329, 2014.
20. Liu YC, Chiang IT, Hsu FT and Hwang JJ: Using NF-kappaB as a molecular target for theranostics in radiation oncology research. Expert Rev Mol Diagn 12: 139-146, 2012.
21. Chiang IT, Liu YC, Wang WH, et al: Sorafenib inhibits TPA-induced MMP-9 and VEGF expression via suppression of ERK/NF-kappaB pathway in hepatocellular carcinoma cells. In vivo 26: 671-681, 2012.
22. Bankston D, Dumas J, Natero R, et al: A scaleable synthesis of BAY 43-9006 a potent Raf kinase inhibitor for the treatment of cancer. Org Process Res Dev 6: 777-781, 2002.
23. Marks PA and Breslow R: Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25: 84-90, 2007.
24. Li F and Sethi G: Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 1805: 167-180, 2010.
25. Galimberti S, Canestraro M, Khan R, et al: Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines. Leukemia 22: 628-631, 2008.
26. Takada Y, Gillenwater A, Ichikawa H and Aggarwal BB: Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 281: 5612-5622, 2006.
27. Chen KF, Chen HL, Tai WT, et al: Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharm Exp Ther 337: 155-161, 2011.
28. Park MA, Zhang G, Martin AP, et al: Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther 7: 1648-1662, 2008.
29. Park MA, Mitchell C, Zhang G, et al: Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res 70: 6313-6324, 2010.
30. Dasari A, Gore L, Messersmith WA, et al: A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs 31: 115-125, 2013.
31. Warlick ED, Cao Q and Miller J: Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodys-plastic syndromes: produces stable disease but at the cost of high toxicity. Leukemia 27: 1789-1791, 2013.
32. Hoang T, Campbell TC, Zhang C, et al: Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. Invest New Drugs 32: 195-199, 2014.
33. Friday BB, Anderson SK, Buckner J, et al: Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol 14: 215-221, 2012.